Catalent, Inc. Reports Fourth Quarter and Full Year 2017 Results

• Q4'17 revenue $616.9 million increased 16% as-reported, or 19% in constant currency from the prior-year period.
• FY'17 revenue $2,075.4 million increased 12% as-reported, or 15% in constant currency from the prior-year period.
• Entered into an exclusive long-term supply agreement to produce the next generation of Pfizer's leading OTC pain relief product with the launch of new Advil Liqui-Gels Minis.
• Increased spray drying and roller compaction capacity at our San Diego, California facility in response to market demand for solubility enhancement solutions.

SOMERSET, N.J.--(BUSINESS WIRE)-- Catalent, Inc. (NYSE:CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced financial results for the fourth quarter and full year of fiscal 2017, which ended June 30, 2017.

Fourth quarter 2017 revenue of $616.9 million increased 16% as reported and increased 19% in constant currency from $532.2 million reported in the fourth quarter a year ago. For fiscal year 2017, revenue was $2,075.4 million and increased 12% as reported and 15% in constant currency, compared to the $1,848.1 million recorded in the prior year. All three of the Company’s reporting segments posted double-digit constant-currency revenue growth for the fourth quarter and fiscal year when compared to the comparable periods of the prior year.

Fourth quarter 2017 net earnings attributable to Catalent were $61.8 million, or $0.49 per diluted share, compared to net earnings of $58.1 million, or $0.46 per diluted share, in the fourth quarter a year ago. For fiscal year 2017, net earnings attributable to Catalent were $109.8 million, or $0.87 per diluted share, compared to net earnings of $111.5 million, or $0.89 per diluted share, in the prior year.

Fourth quarter 2017 EBITDA from continuing operations of $130.5 million, as referenced in the GAAP to non-GAAP reconciliation provided later in this release, decreased 3% from $134.4 million in the fourth quarter a year ago. For fiscal year 2017, EBITDA from continuing operations was $372.2 million, in-line with the $374.3 million recorded in the prior year.

Fourth quarter 2017 Adjusted EBITDA (see the non-GAAP reconciliation for a discussion of this metric) was $159.1 million, or 25.8% of revenue, compared to $141.8 million, or 26.6% of revenue, in the fourth quarter a year ago. This represents an increase of 12% as reported and an increase of 15% on a constant-currency basis.

Fourth quarter 2017 Adjusted Net Income (see the non-GAAP reconciliation) was $82.6 million, or $0.65 per diluted share, compared to Adjusted Net Income of $64.9 million, or $0.52 per diluted share, in the fourth quarter a year ago.

"We're pleased with our performance during the fourth quarter, where we recorded double-digit organic revenue growth and segment EBITDA growth on a constant-currency basis across all three of our reporting segments," said John Chiminski, Chairman, President and Chief Executive Officer of Catalent, Inc. "Fiscal year 2017 was strong across many fronts with financial performance above our long-term outlook, significant levels of free cash flow generation, and the completion of two strategic acquisitions, Pharmatek and Accucaps, both of which are already creating value for the company and our shareholders."

Fourth Quarter 2017 Segment Highlights

Revenue Highlights by Business Segment

Revenue from the Softgel Technologies segment was $257.1 million for the fourth quarter of fiscal 2017, an increase of 14% as reported, or 16% in constant currency, compared to the fourth quarter a year ago. The constant-currency growth was attributable to higher end-market demand for prescription products in Europe. Increased demand for prescription and consumer health products in North America also contributed to the growth, but was partially offset by lower end-market demand for consumer health products in Asia Pacific. The acquisition of Accucaps contributed 14 percentage points of the segment's constant-currency revenue growth during the quarter.

Revenue from the Drug Delivery Solutions segment was $270.2 million for the fourth quarter of fiscal 2017, an increase of 13% as reported, or 16% in constant currency, over the fourth quarter a year ago. The growth was primarily driven by favorable end-customer demand for certain higher margin offerings within our oral delivery solutions platform and increased volume related to our biologics offerings. The acquisition of Pharmatek contributed 3 percentage points of the segment's constant-currency revenue growth during the quarter.

Revenue from the Clinical Supply Services segment was $99.3 million for the fourth quarter of fiscal 2017, an increase of 22% as reported, or an increase of 28% in constant currency over the fourth quarter a year ago. This growth was due to higher volume related to core storage, distribution, manufacturing, and packaging services; as well as due to increased lower-margin comparator sourcing activities.

Segment EBITDA Highlights

Softgel Technologies segment EBITDA (see the discussion of non-GAAP measures below) in the fourth quarter of fiscal 2017 was $65.2 million, an increase of 11% as reported, or 13% in constant currency, versus the fourth quarter a year ago. The increase was primarily attributable to increased volume for prescription products in Europe and North America; partially offset by lower end-market demand for consumer health products in Asia Pacific. The acquisition of Accucaps contributed 9 percentage points of the constant-currency growth in the segment EBITDA during the quarter.

Drug Delivery Solutions segment EBITDA in the fourth quarter of fiscal 2017 was $90.9 million, an increase of 20% as reported, or 23% in constant currency. The increase was primarily driven by increased demand for certain higher margin offerings with our oral delivery solutions platform, and increased volume related to our biologics offerings. The acquisition of Pharmatek contributed 2 percentage points of the growth in segment EBITDA during the quarter.

Clinical Supply Services segment EBITDA in the fourth quarter of fiscal 2017 was $17.1 million, an increase of 25% as reported, or 34% in constant currency. The increase was primarily attributable to higher demand for our core storage, distribution, manufacturing and packaging services. Increased volume related to lower-margin comparator sourcing activities also modestly contributed to the segment's EBITDA growth.

Fiscal 2017 Segment Highlights

Revenue Highlights by Business Segment

Revenue from the Softgel Technologies segment was $855.3 million for fiscal year 2017, an increase of 10% as reported, or 12% in constant currency, compared to a year ago. The constant-currency growth was attributable to higher end-market demand for prescription products in Europe, which includes increased volume at a facility that produced at lower production levels in the prior year due to a temporary suspension. Increased demand for prescription and consumer health products in North America also contributed to the growth, but this was partially offset by lower end-market demand for consumer health products in Asia Pacific. The acquisition of Accucaps contributed 6 percentage points of the segment's constant-currency revenue growth during the period.

Revenue from the Drug Delivery Solutions segment was $910.1 million for fiscal year 2017, an increase of 13% as reported, or 16% in constant currency, over a year ago. The strong performance was primarily driven by favorable end-customer demand for certain higher margin offerings within our U.S. oral delivery solutions platform, increased volume related to our biologics offerings, and increased activity within the analytical services platform. The acquisition of Pharmatek contributed 3 percentage points of the segment's constant-currency revenue growth during the fiscal year.

Revenue from the Clinical Supply Services segment was $348.8 million for fiscal year 2017, an increase of 13% as reported, or an increase of 20% in constant currency over the prior year. This growth was due to higher volume related to core storage, distribution, manufacturing, and packaging services; as well as due to increased lower-margin comparator sourcing activities.

Segment EBITDA Highlights

Softgel Technologies segment EBITDA for fiscal year 2017 was $190.5 million, an increase of 16% as reported, or 20% in constant currency, compared to a year ago. The increase was primarily attributable to a favorable mix shift to higher margin prescription products in Europe and North America, and increased volume and reduced costs at the facility that was suspended in the prior year. The acquisition of Accucaps contributed 5 percentage points of the constant-currency segment EBITDA growth during the period.

Drug Delivery Solutions segment EBITDA in fiscal year 2017 was $242.4 million, an increase of 13% as reported, or 17% in constant currency, over the prior year, due to increased volume and favorable product mix within our analytical services platform and biologics offerings, as well as due to increased volumes related to our integrated oral solids development and manufacturing capabilities within our oral delivery solutions platform. The acquisition of Pharmatek contributed 2 percentage points of the constant-currency segment EBITDA growth during the fiscal year.

Clinical Supply Services segment EBITDA in fiscal year 2017 was $54.9 million, an increase of 3% as reported, or 14% in constant currency, compared to a year ago. The increase was primarily attributable to higher demand for our core storage, distribution, manufacturing and packaging services. Increased volume related to lower-margin comparator sourcing activities also modestly contributed to the segment EBITDA growth.

Additional Financial Highlights

Fourth quarter 2017 gross margin of 34.8% decreased 50 basis points as-reported, from 35.3% in the fourth quarter a year ago. The decrease was primarily attributable to unfavorable product mix within the Softgel Technologies segment and the addition of the Accucaps acquisition. Gross margin of 31.5% in fiscal year 2017 declined 30 basis points as-reported, from the 31.8% recorded a year ago. The decline was primarily attributable to unfavorable product mix within the Clinical Supply Services segment.

Fourth quarter 2017 selling, general and administrative expenses were $107.3 million and represented 17.4% of revenue, compared to $89.5 million, or 16.8% of revenue, in the fourth quarter a year ago. Selling, general and administrative expenses for fiscal year 2017 were $402.6 million and represented 19.4% of revenue, compared to $358.1 million, or 19.4% of revenue, in the prior year.

Backlog for the Clinical Supply Services segment, defined as estimated future service revenues from work not yet completed under signed contracts was $338.3 million as of June 30, 2017, a 3% increase compared to the third quarter of fiscal year 2017. The segment also recorded net new business wins of $111.2 million during the fourth quarter, which represented a 4% increase year over year. The segment’s trailing-twelve-month book-to-bill ratio was 1.1x.

Balance Sheet and Liquidity

As of June 30, 2017, Catalent had $2.1 billion in total debt, and $1.8 billion in total debt net of cash and short-term investments, which is essentially in-line with the total and net debt levels as of March 31, 2017. As of June 30, 2017, Catalent’s total net leverage ratio was 4.0x, an improvement compared to the 4.2x recorded in the prior quarter and the 4.3x recorded at the end of fiscal year 2016.

Fiscal Year 2018 Outlook

For fiscal year 2018, the company expects revenue in the range of $2.16 billion to $2.24 billion. Catalent expects Adjusted EBITDA in the range of $477 million to $497 million and Adjusted Net Income in the range of $192 million to $212 million. These guidance ranges continue to be consistent with the organic, constant-currency long-term CAGR growth expectations of 4-6% for revenue and 6-8% for Adjusted EBITDA. The Company expects self-funded capital expenditures in the range of $145 million to $155 million and fully diluted share count in the range of 127 million to 129 million shares on a weighted-average basis.

Earnings Webcast

The Company’s management will host a webcast to discuss the results at 4:45 p.m. ET today. Catalent invites all interested parties to listen to the webcast, which will be accessible through Catalent’s website at http://investor.catalent.com. A supplemental slide presentation will also be available in the “Investors” section of Catalent’s website prior to the start of the webcast. The webcast replay, along with the supplemental slides, will be available for 90 days in the “Investors” section of Catalent’s website at www.catalent.com.

About Catalent, Inc.

Catalent, Inc. (NYSE: CTLT) is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs over 10,000 people, including over 1,400 scientists, at more than 30 facilities across 5 continents and in fiscal 2017 generated over $2 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, please visit www.catalent.com.

Non-GAAP Financial Measures

Use of EBITDA from continuing operations, Adjusted EBITDA, Adjusted Net Income and Segment EBITDA

Management measures operating performance based on consolidated earnings from continuing operations before interest expense, expense/(benefit) for income taxes, and depreciation and amortization, and it is adjusted for the income or loss attributable to non-controlling interest (“EBITDA from continuing operations”). EBITDA from continuing operations is not defined under U.S. GAAP and is not a measure of operating income, operating performance or liquidity presented in accordance with U.S. GAAP and is subject to important limitations.

The Company believes that the presentation of EBITDA from continuing operations enhances an investor’s understanding of its financial performance. The Company believes this measure is a useful financial metric to assess its operating performance from period to period by excluding certain items that it believes are not representative of its core business and uses this measure for business planning purposes.

In addition, given the significant investments that Catalent has made in the past in property, plant and equipment, depreciation and amortization expenses represent a meaningful portion of its cost structure. The Company believes that EBITDA from continuing operations will provide investors with a useful tool for assessing the comparability between periods of its ability to generate cash from operations sufficient to pay taxes, to service debt and to undertake capital expenditures because it eliminates depreciation and amortization expense. The Company presents EBITDA from continuing operations in order to provide supplemental information that it considers relevant for the readers of the Consolidated Financial Statements, and such information is not meant to replace or supersede U.S. GAAP measures. The Company’s definition of EBITDA from continuing operations may not be the same as similarly titled measures used by other companies.

Catalent evaluates the performance of its segments based on segment earnings before non-controlling interest, other (income)/expense, impairments, restructuring costs, interest expense, income tax expense/(benefit), and depreciation and amortization (“segment EBITDA”). Moreover, under the Company's credit agreement, its ability to engage in certain activities, such as incurring certain additional indebtedness, making certain investments and paying certain dividends, is tied to ratios based on Adjusted EBITDA, which is not defined under U.S. GAAP and is subject to important limitations. Adjusted EBITDA is the covenant compliance measure used in the credit agreement governing debt incurrence and restricted payments. Because not all companies use identical calculations, the Company’s presentation of Adjusted EBITDA may not be comparable to other similarly titled measures of other companies.

Management also measures operating performance based on Adjusted Net Income/(loss) and Adjusted Net Income/(loss) per share. Adjusted Net Income/(loss) is not defined under U.S. GAAP and is not a measure of operating income, operating performance or liquidity presented in accordance with U.S. GAAP and is subject to important limitations. The Company believes that the presentation of Adjusted Net Income/(loss) and Adjusted Net Income/loss per share enhances an investor’s understanding of its financial performance. The Company believes this measure is a useful financial metric to assess its operating performance from period to period by excluding certain items that it believes are not representative of its core business and the Company uses this measure for business planning purposes. The Company defines Adjusted Net Income/(loss) as net earnings/(loss) adjusted for (1) earnings or loss of discontinued operations, net of tax, (2) amortization attributable to purchase accounting and (3) income or loss from non-controlling interest in its majority-owned operations. The Company also makes adjustments for other cash and non-cash items included in the table below, partially offset by its estimate of the tax effects as a result of such cash and non-cash items. The Company believes that Adjusted Net Income/(loss) and Adjusted Net Income/(loss) per share will provide investors with a useful tool for assessing the comparability between periods of its ability to generate cash from operations available to its stockholders. The Company’s definition of Adjusted Net Income/(loss) may not be the same as similarly titled measures used by other companies.

The most directly comparable GAAP measure to EBITDA from continuing operations and Adjusted EBITDA is earnings/(loss) from continuing operations. The most directly comparable GAAP measure to Adjusted Net Income/(loss) is net earnings/(loss). Included in this release is a reconciliation of earnings/(loss) from continuing operations to EBITDA from continuing operations and Adjusted EBITDA and a reconciliation of net earnings/(loss) to Adjusted Net Income.

The Company does not provide a reconciliation of forward-looking non-GAAP financial measures to their comparable GAAP financial measures because it could not do so without unreasonable effort due to the unavailability of the information needed to calculate reconciling items and due to the variability, complexity and limited visibility of the adjusting items that would be excluded from the non-GAAP financial measures in future periods. When planning, forecasting and analyzing future periods, the Company does so primarily on a non-GAAP basis without preparing a GAAP analysis as that would require estimates for various cash and non-cash reconciling items that would be difficult to predict with reasonable accuracy. For example, equity compensation expense would be difficult to estimate because it depends on the Company’s future hiring and retention needs, as well as the future fair market value of the Company’s common stock, all of which are difficult to predict and subject to constant change. It is equally difficult to anticipate the need for or magnitude of a presently unforeseen one-time restructuring expense or the values of end-of-period foreign currency exchange rates. As a result, the Company does not believe that a GAAP reconciliation would provide meaningful supplemental information about the Company’s outlook.

Use of Constant Currency

As changes in exchange rates are an important factor in understanding period-to-period comparisons, the Company believes the presentation of results on a constant currency basis in addition to reported results helps improve investors’ ability to understand its operating results and evaluate its performance in comparison to prior periods. Constant currency information compares results between periods as if exchange rates had remained constant period over period. The Company uses results on a constant currency basis as one measure to evaluate its performance. The Company calculates constant currency by calculating current-year results using prior-year foreign currency exchange rates. The Company generally refers to such amounts calculated on a constant currency basis as excluding the impact of foreign exchange or being on a constant currency basis. These results should be considered in addition to, not as a substitute for, results reported in accordance with U.S. GAAP. Results on a constant currency basis, as the Company presents them, may not be comparable to similarly titled measures used by other companies and are not measures of performance presented in accordance with U.S. GAAP.

Forward-Looking Statements

This release contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by the use of statements that include phrases such as “believe,” “expect,” “anticipate,” “intend,” “estimate,” “plan,” “project,” “foresee,” “likely,” “may,” “will,” “would” or other words or phrases with similar meanings. Similarly, statements that describe the Company’s objectives, plans or goals are, or may be, forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Catalent, Inc.’s expectations and projections. Some of the factors that could cause actual results to differ include, but are not limited to, the following: participation in a highly competitive market and increased competition may adversely affect the business of the Company; demand for the Company’s offerings which depends in part on the Company’s customers’ research and development and the clinical and market success of their products; product and other liability risks that could adversely affect the Company’s results of operations, financial condition, liquidity and cash flows; failure to comply with existing and future regulatory requirements; failure to provide quality offerings to customers could have an adverse effect on the Company’s business and subject it to regulatory actions and costly litigation; problems providing the highly exacting and complex services or support required; global economic, political and regulatory risks to the operations of the Company; inability to enhance existing or introduce new technology or service offerings in a timely manner; inadequate patents, copyrights, trademarks and other forms of intellectual property protections; fluctuations in the costs, availability, and suitability of the components of the products the Company manufactures, including active pharmaceutical ingredients, excipients, purchased components and raw materials; changes in market access or healthcare reimbursement in the United States or internationally; fluctuations in the exchange rate of the U.S. dollar and other foreign currencies including as a result of the recent U.K. referendum to exit from the European Union; adverse tax legislation initiatives or challenges to the Company’s tax positions; loss of key personnel; risks generally associated with information systems; inability to complete any future acquisitions and other transactions that may complement or expand the business of the Company or divest of non-strategic businesses or assets and the Company’s ability to successfully integrate acquired business and realize anticipated benefits of such acquisitions; offerings and customers’ products that may infringe on the intellectual property rights of third parties; environmental, health and safety laws and regulations, which could increase costs and restrict operations; labor and employment laws and regulations; additional cash contributions required to fund the Company’s existing pension plans; substantial leverage resulting in the limited ability of the Company to raise additional capital to fund operations and react to changes in the economy or in the industry, exposure to interest rate risk to the extent of the Company’s variable rate debt and preventing the Company from meeting its obligations under its indebtedness. For a more detailed discussion of these and other factors, see the information under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2017, filed today with the Securities and Exchange Commission. All forward-looking statements speak only as of the date of this release or as of the date they are made, and Catalent, Inc. does not undertake to update any forward-looking statement as a result of new information or future events or developments except to the extent required by law.

More products. Better treatments. Reliably supplied.™

Refer to the Company's description of non-GAAP measures including segment EBITDA as referenced above.

Refer to the Company's description of non-GAAP measures including segment EBITDA as referenced above.

(1) Please refer to note 14 of the consolidated financial statements within our Annual Report on Form 10-K for the year ended June 30, 2017.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170828005923/en/

Investors:

Catalent, Inc.

Thomas Castellano, 732-537-6325

[email protected]

Source: Catalent, Inc.